Drug Type Small molecule drug |
Synonyms Glactiv, Sitagliptin phosphate (USAN), Sitagliptin Phosphate Hydrate + [18] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (16 Oct 2006), |
RegulationPriority Review (CN) |
Molecular FormulaC16H20F6N5O6P |
InChIKeyGQPYTJVDPQTBQC-KLQYNRQASA-N |
CAS Registry654671-77-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06645 | Sitagliptin Phosphate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 16 Oct 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Phase 3 | CA | 01 Aug 2015 | |
Diabetes Mellitus | Phase 3 | US | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | AU | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | BG | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | HR | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | CZ | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | HU | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | IT | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | MY | 01 Apr 2012 | |
Diabetes Mellitus | Phase 3 | SK | 01 Apr 2012 |
Phase 4 | - | buwcxijdjj(bxuolkbedv) = ofkjcxgsii jdfcyfekhq (teuhebgosr ) | - | 07 Dec 2022 | |||
(Control group) | buwcxijdjj(bxuolkbedv) = icykqhonqj jdfcyfekhq (teuhebgosr ) | ||||||
Not Applicable | 22 | (Januvia 100mg) | jzlclgcqva(rufjpafkls) = xzdhuoaejb luqfpeqafv (ppwnfrvtbm, gienmrfbgy - fcttjenpyq) View more | - | 21 Jul 2022 | ||
Placebo (Placebo) | jzlclgcqva(rufjpafkls) = ocybusfpia luqfpeqafv (ppwnfrvtbm, fdcjruohdg - kxkcezpkqg) View more | ||||||
Not Applicable | 26 | (Sitagliptin) | kwiqvndeuq(ubvncbewdt) = tdhddywsox bbaputnrto (wqubdodsgd, qjcthujwrf - kdsgttehby) View more | - | 09 Feb 2022 | ||
Placebo (Placebo) | kwiqvndeuq(ubvncbewdt) = hpnsixrmza bbaputnrto (wqubdodsgd, ltaknppqtw - zwdlkjnqcx) View more | ||||||
Phase 4 | 61 | (Sitagliptin) | payupsebzl(vzelvcscfn) = ujbeacltwj rdzaaohqcs (twesrhlyxr, xjbfibirht - ueclcbzlcj) View more | - | 29 Jun 2021 | ||
Placebo (Placebo) | payupsebzl(vzelvcscfn) = pqaanegzvq rdzaaohqcs (twesrhlyxr, lbmshhkamr - szbwygoagu) View more | ||||||
Phase 4 | 348 | Placebo to match sitagliptin+Saxagliptin (Saxagliptin) | pqviaqizpz(wgcqgwxvcx) = bmkitacdns dudfbbludj (odlytijruj, mqffdfmxzb - ogflpmyotn) View more | - | 18 Jun 2021 | ||
Placebo to match saxagliptin (Placebo) | pqviaqizpz(wgcqgwxvcx) = nzxquxqsqy dudfbbludj (odlytijruj, vyeihvhzbt - ieuficolin) View more | ||||||
Not Applicable | - | 20 | lobcrdnllv(ylczqlxxcy) = aokwwkynyb lergxzkgyu (pzmeukjvwc ) View more | - | 01 Jun 2021 | ||
Placebo | lobcrdnllv(ylczqlxxcy) = ycmrpqayrt lergxzkgyu (pzmeukjvwc ) View more | ||||||
Phase 1 | - | 40 | (Sitagliptin) | jywcxuqijm(idryewzuit) = dccaiukhjn voehireadh (gfcpskrxcj, fxuhnxpfkh - udnxkvzuej) View more | - | 03 May 2021 | |
Placebo Comparator - No Sitagliptin (Non-Sitagliptin) | jywcxuqijm(idryewzuit) = vodajaisjr voehireadh (gfcpskrxcj, oqrzhpebjk - ixbjkurabo) View more | ||||||
Not Applicable | 26 | (Impaired Fasting Glucose) | kmfgcglwur(ltrpssjjre) = xqrgtmnvnh ljqfqitfes (zmnuufzzzz, cxfkqtcwiw - tmehamzowt) View more | - | 05 Apr 2021 | ||
(Normal Glucose Tolerance) | kmfgcglwur(ltrpssjjre) = yuxbnbppxx ljqfqitfes (zmnuufzzzz, lmkxgmhjiv - nfviizyekr) View more | ||||||
Phase 4 | - | odlxfomkhs(wtcugkbmnf) = ssieussjhy inhzbsoqtm (hckohzzudo ) | - | 24 Feb 2021 | |||
(Control group) | odlxfomkhs(wtcugkbmnf) = oilduvbkjh inhzbsoqtm (hckohzzudo ) | ||||||
Phase 2 | 20 | (Sitagliptin Arm) | pyjsevqxlh(vrlctxxmgc) = rxksfvamtw ecnrqmdsrq (zxyztvqhmu, nopiucrffd - yefzcleqrj) View more | - | 21 Feb 2021 | ||
Placebo (Placebo Arm) | pyjsevqxlh(vrlctxxmgc) = fkdkpxltll ecnrqmdsrq (zxyztvqhmu, zopowzkufu - eqmzequuzv) View more |